RIDDLE&CODE
17.3.2022 10:17:06 CET | Business Wire | Press release
The consortium formed by Dyne.org, RIDDLE&CODE and InfoCert has entered the second phase of the European Blockchain Services Infrastructure (EBSI) project and will receive support to further develop and test its multilayered blockchain stack ZENBRIDGE.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220317005181/en/
Led by the European Commission and 29 member countries that collaborate as a European Blockchain Partnership (EBP), EBSI aims to develop highly secure and compliant cross-border public services on a European level. This involves overcoming gaps in the existing blockchain applications and delivering more demanding solutions that reduce environmental footprint and comply with EU legal frameworks such as the GDPR. The second phase of the project was launched on December 20, 2021, and will run until the end of June 2022.
Some use cases include management and exploitation of data, tracking of digital records and the rights associated with them, automation of tasks through smart contracts and development of incentive models through tokenization of both physical and digital assets.
ZENBRIDGE, a state-of-the-art decentralized system, offers distributed, secure execution of smart contracts and is integrated with blockchain frameworks such as BigchainDB, PlanetMINT, Ethereum, Hyperledger Fabric, Hyperledger Sawtooth and Bitcoin. The system is designed to deliver high-velocity performance, ensure sustainability and provide superior levels of data sovereignty as well as interoperability between various blockchain networks and legacy systems.
During this second phase, research and development results will be lab-tested. Based on these outcomes, a minimum of three projects will be selected for the final Phase (2B), which will run for an additional 12 months and result in real-world field testing.
Quotes from the consortium members:
Thomas Fürstner (Founder & CTO, RIDDLE&CODE): “The expertise of our consortium will hopefully convince the European Commission to make use of blockchain technology as a multipurpose tool to secure both the value of digital assets and data. At the ‘layer zero’, RIDDLE&CODE will work to connect productive machines and sensors with the security of banking-grade backends. This will allow us to establish trusted digital product passports for physical items in motion across Europe and ensure compliance with the European regulatory frameworks in a transparent way.”
Denis “Jaromil” Roio , (Founder and CTO of Dyne.org): “In our success within the EBSI procurement process, we see a big opportunity to provide the European ICT industry with environmentally sustainable solutions that are free and open to community-based adoption models. We leverage cryptography beyond some common financial sector use cases, making it easy to retrofit and recycle legacy infrastructure. Our solution is free from the speculation and waste of crypto-markets, supports computation on low-power embedded hardware and supports future-proof building blocks that are quantum-resistant. With the ZENBRIDGE stack, a developer can go from a smart contract to a ready-to-use wallet app implementation for digital product passports in a week.”
Carmine Auletta (Chief Strategy and Innovation Officer, InfoCert - Tinexta Group): “We’re pleased with the results achieved by the consortium in Phase 1 and proud of the support and trust placed in us to further develop the project in its second phase. Distributed Ledger Technologies will play an important role in the EU digital market and a key component to their market uptake will inevitably be played by their Governance & Trust Framework. Our consortium partners have demonstrated extraordinary technical expertise in distributed ledger technologies, while InfoCert has very distinctive experience in creating Trust Frameworks. Joining forces has proved crucial to ZENBRIDGE’s success.”
About RIDDLE&CODE
RIDDLE&CODE is Europe’s leading company for blockchain interface solutions. The company develops hardware and software stacks that combine the security of smart cards with blockchain and the Internet of Things (IoT). Together with its tier-one clients and partners, which include Daimler Mobility, BMW, Wien Energie and leading Dutch crypto exchange LiteBit, RIDDLE&CODE brings new business models to the fintech, energy, mobility and materials industries.
More information: www.riddleandcode.com
About Dyne.org
Dyne.org is a non-profit foundation dedicated to free and open-source software and community development with 20 years of expertise in developing applications used worldwide. With the motto “we are free to share code and we code to share freedom”, its projects include independent streaming software for free speech, privacy tools for activists and GNU/Linux distributions.
More information: dyne.org
About InfoCert
InfoCert, Tinexta Group, is the largest European certification authority, active in over twenty countries. The company provides services in digitisation, eDelivery, Digital Signature and digital preservation of documents and is an accredited AgID digital identity operator in the area of SPID (Public System for the management of Digital Identity). The company holds a 60% stake in CertEurope, the biggest certification authority in France; a 51% stake in Camerfirma, one of the principal Spanish certification authorities; a 16.7% stake in Authada, a leading-edge German Identity Provider; and 80% of Sixtema S.p.A.
More information: infocert.digital
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005181/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom